Effects of long-term exposure to glucosamine and mannosamine (cas 2636-92-2) on aggrecan degradation in articular cartilage

Add time:07/14/2019    Source:sciencedirect.com

Objective: To investigate the effect of long-term exposure to glucosamine or mannosamine (cas 2636-92-2) on the catabolism of aggrecan by explant cultures of bovine articular cartilage maintained in the presence of retinoic acid.Design: The kinetics of loss of 35S-labeled and total aggrecan from explant cultures of bovine articular cartilage maintained in the presence of 1 μM retinoic acid and exposed to varying concentrations of glucosamine or mannosamine was investigated over a 9-day culture period. In other experiments, the reversibility of the inhibition of aggrecan catabolism by glucosamine or mannosamine was investigated in cultures exposed to these amino sugars for the first 5 days of a 15-day culture period. The metabolism of chondrocytes exposed to these amino sugars was evaluated by measurement of lactate production or 3H-serine and 35S-sulfate incorporation into protein and glycosaminoglycans, respectively. The direct effect of these amino sugars on soluble aggrecanase activity was determined from immunoblots of aggrecan digests.Results: Glucosamine at 5 mM concentration and mannosamine at 2 mM concentration inhibited degradation of radiolabeled and chemical levels of aggrecan. At concentrations of up to 10 mM amino sugars, the metabolism of chondrocytes was not impaired, as determined by lactate production, protein synthesis and the incorporation of 35S-sulfate into proteoglycans. These amino sugars did not inhibit soluble aggrecanase activity. The exposure of articular cartilage explants to 5 mM glucosamine or mannosamine for 5 days in culture in the presence or absence of retinoic acid did not provide long-term suppression of stimulated aggrecan loss.Conclusions: This study indicates that continuous presence of amino sugars is required to protect cartilage from stimulated loss of aggrecan.

We also recommend Trading Suppliers and Manufacturers of mannosamine (cas 2636-92-2). Pls Click Website Link as below: cas 2636-92-2 suppliers

Prev:mannosamine (cas 2636-92-2) can replace glucosamine in glycosylphosphatidylinositols of Plasmodium falciparum in vitro
Next:Immunoadjuvant capacity of flagellin and mannosamine (cas 2636-92-2)-coated poly(anhydride) nanoparticles in oral vaccination)